References
- Silverman LR, Demakos EP, Peterson BL, . Randomized, controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429–2440.
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, ; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 2009;10:223–232.
- Itzkynson R, Thepot S, Quesnel B, ; Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403–411.
- Vardiman JW, Thiele J, Arber DA, . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937–951.
- Cheson BD, Greenberg PL, Bennett JM, . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–425.
- Campelo MD, Delgado RG, Godoy Molias AC, . Azacitidine for the treatment of myelodysplastic syndromes in the elderly. Adv Ther 2011;28:10–15.
- Seymour JF, Fenaux P, Silverman LR, . Effects of azacitidine compared with conventional care regimens in elderly (>75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010;76:218–227.